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Abstract 
 
Heart failure (HF) is associated with an increased risk of thrombotic events, 
particularly if this condition is accompanied by atrial fibrillation (AF). Many HF 
patients have background coronary artery disease (CAD) making them prone to 
coronary thrombosis resulting in myocardial infarction or sudden death. Oral 
anticoagulation is essential in the vast majority of HF patients with AF with non-
vitamin K based anticoagulants being a suitable alternative to warfarin. In contrast, 
aspirin alone does not provide adequate stroke prevention in such patients. In HF 
without AF, oral anticoagulation should not be routinely used, and antiplatelet agents 
should be prescribed in patients with background CAD. This review provides an 
overview of prothrombotic factors and antithrombotic management of patients with 
HF. 
 
Key words: heart failure, thrombosis, oral anticoagulants, atrial fibrillation 
Abbreviations: 
AF: Atrial fibrillation 
CAD: Coronary artery disease 
HF:Heart failure 
HFrEF: Heart failure with reduced ejection fraction 
LA: Left atrium or atrial 
LAA:Left atrial  appendage 
LV:Left ventricle or ventricular 
LVEF: Left ventricular ejection fraction 
NSR:Normal sinus rhythm 
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NYHA:New York Heart Association 
NVAF: Non-valvular atrial fibrillation 
SCD:Sudden cardiac death 
VTE: Venous thromboembolism 
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Introduction 
 
Heart failure (HF) has been associated with increased risk of thrombotic events that 
affected a third of HF patients.
1
 Poor mobility and multiple co-morbidities predispose 
to occurrence of venous thromboembolism (VTE).
2, 3
 The risks are particularly high 
in patients with acute HF decompensation who require hospital admission with VTE 
reported in up to half of such patients, unless  VTE prophylaxis is given.
2, 3
 Many HF 
patients have background coronary artery disease (CAD) making them prone to 
coronary thrombosis resulting in myocardial infarction  or sudden cardiac death 
(SCD).
4
 Patients with HF are also at increased risk of ischaemic stroke, which has 
been reported to occur in 2% of such patients within the first year of presentation.
5
 In 
fact, about 20% of patients with ischemic stroke have impaired left ventricular (LV) 
systolic function.
6
  
 
The risk of stroke and systemic VTE is especially high in patients with concomitant 
atrial fibrillation (AF), which is extremely common in subjects with HF irrespectively 
of LV ejection fraction ( LVEF). Literature suggests that up to 40% of HF patients 
may experience the arrhythmia.
7, 8
 In patients with HF and preserved LVEF , AF was 
associated with approximately 3-fold higher risk of ischaemic stroke compared to 
those with no history of the arrhythmia.
9
 In patients with HF with reduced LVEF 
(HFrEF),the presence of AF carries a 2-fold increased risk of ischaemic stroke and 
systemic VTE compared to those in  normal sinus rhythm (NSR).
10
 All major clinical 
guidelines on management of AF recognise HF as a major risk factor for stroke.
11, 12
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Moreover, the true rate of AF can be underestimated due to possibility of ‘silent’ AF. 
A retrospective analysis of multicentre trials of cardiac resynchronization therapy in 
HF demonstrated the presence of AF episodes in a third of patients and it was 
frequently ‘silent’.13 The study also showed that even short (e.g., 10 min) paroxysms 
of ‘silent’ AF might have significant clinical consequences, being associated with 2-
fold increased risk of deaths or hospital admission for HF. 
 
 
The prothrombotic state in heart failure 
 
Congestive HF and AF share a number of common pathophysiological processes 
producing a multifactorial prothrombotic milieu.  
 
First, both HF and AF are characterized by impaired cardiac and/or systemic 
haemodynamics predisposing to blood stasis. In AF  atrial stasis is caused by lack of 
synchronous contractility of atrial cardiomyocytes, resulting in absence of efficient 
atrial systole. The stasis is most prominent within the left atrial (LA) appendage 
(LAA), which has no ‘through flow’ and where the blood flow ultimately depends on 
efficient synchronous contraction of the appendage cardiomyocytes. It is not 
surprising that the LAA is the most frequent site of thrombus formation in AF;
14
 LA 
dilation has been shown to be independently associated with increased risk for stroke 
even after adjustment for other recognized stroke risk factors.
15, 16
 The right atrial 
appendage is less prone to thrombus generation as it is smaller and shallower than its 
left sided counterpart. Intracardiac blood stasis in AF is reflected by increased levels 
of brain natriuretic peptides despite preserved LVcontractility.
17
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Blood stasis in AF is not solely restricted to the atria and AF does contribute to 
systemic stasis as absence of atrial systole disturbs LV diastolic filling and cardiac 
stroke volume. The impact is even more prominent when it occurs in the presence of 
other conditions predisposing to local or systemic blood stasis. 
 
Flow congestion in HF is clearly noticeable within the failing LV especially if 
patients have severe regional wall motion abnormalities in the apical area (e.g., in 
post myocardial infarction aneurism). Severe deterioration in systolic LV function 
leads to peripheral congestion and severe blood stasis.  
 
In fact, HF frequently co-exists with AF, with 13 to 40 per cent of HF patients having 
AF irrespectively of LVEF.
7, 8
 Atrial fibrillation potentiates intracardiac and 
extracardiac blood stasis in patients with HF, thus predisposing to stroke and systemic 
VTE. Occurrence of AF in HF further deteriorates already impaired systemic 
perfusion as effective atrial contraction in sinus rhythm contributes up to 25% of the 
cardiac output.
18
 
19
  
 
Second, patients with HF have prominent endothelial dysfunction, irrespectively of 
HF aetiology.
20
 The presence of endothelial dysfunction in HF bears increased 
mortality and risk of hospital re-admissions. Endothelial dysfunction parallels and 
predisposes to chronic proinflammatory state and increased oxidative stress, which 
promotes thrombogenesis.
21, 22 
Presence of congestive HF further augments 
endothelial dysfunction already evident in HF.
21-23
 Small areas of endothelial 
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denudation and thrombus formation have been described in atrial fibrillation 
complicated by cerebral embolism.  
 
Third, the final component of Virchow’s triad in HF is evident by an imbalance in 
pro- and antithrombotic factors with clear prothrombotic shift overall. Patients with 
HF have increased levels of plasma fibrinogen, fibrinopeptide A and fibrin D-dimer. 
21, 24, 25
 Furthermore, the presence of endothelial dysfunction in HF has profound 
implication on production of haemostatic and fibrinolytic factors in HF with net effect 
favouring prothrombotic changes
20, 26
 
 
 
Thrombosis prevention in heart failure with atrial fibrillation 
 
In almost 100,000 patients admitted with HF and enrolled in Get With The 
Guidelines-HF programme, AF was independently associated with poor outcome.
27
 
Current guidelines on management of patients with AF suggest administration of oral 
anticoagulation in virtually all HF patients without contraindications.
28, 29
 Indeed, HF 
per se puts patents in the category of CHA2DS2-VASc score ≥1, where oral 
anticoagulation is advisable with majority of patients having at least one other risk 
factor thus making oral anticoagulation mandated (i.e., score ≥2). As a result oral 
anticoagulation should be routinely used in HF with concomitant AF.
28, 30
  
 
All patients started on oral anticoagulation with warfarin or other vitamin K 
antagonists must have regular monitoring of international normalised ratio (INR), 
with target recommended INR value of 2.0-3.0 in non-valvular AF (NVAF).
31, 32
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Anticoagulation with warfarin brings many challenges, given the high inter- and intra-
patient variability in INRs, requiring regular anticoagulation monitoring.  A high time 
in therapeutic range (TTR, ie. >70%) is needed to ensure the best outcomes in 
efficacy and safety
33-35
;  TTRs can be influenced by multiple clinical risk factors, 
which have been incorporated into the SAMe-TT2R2 score to help identify those 
patients who are likely to do well on warfarin
36-38
.  
 
Real world data indicate that oral anticoagulation in AF is often underutilised, with 
fear of perceived risk of bleeding complications being the most common reason of not 
prescribing of the indicated treatment.
26
 Although oral anticoagulants should be 
avoided in patients with genuine high risk of bleeding (e.g., coagulopathy) such 
patients are uncommon. To avoid inadequate stroke prevention in HF accompanied by 
AF, all such patients should have bleeding risk quantification using the recommended 
HAS-BLED score.
28, 39, 40
 In subjects with HAS-BLED score ≥3, risks and benefits of 
oral anticoagulation should be individually considered and if started the therapy needs 
to be regularly reviewed to ensure its safety. 
 
Although aspirin is frequently used in patients with HF and NSR, it does not provide 
adequate protection against stroke or systemic VTE in people with AF. In those few 
patients where oral anticoagulants are genuinely contraindicated due to high risk of 
bleeding, aspirin bears similar risk of bleeding to warfarin  without providing 
effective prevention of VTE events; and it should be avoided unless the patient has 
CAD.  
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In view of the profound difference in the risk of stroke and systemic VTE between HF 
patients with and without AF, should restoration of  NSR be the goal  in patients with 
persistent AF? A comparison of the two approaches was performed in the randomised 
Atrial Fibrillation and Congestive Heart Failure (AF-CHF) study 
41
. The trial 
recruited 1376 patients with LVEF <35% who were followed for an average of 3 
years. The study found no difference in rates of stroke between the two groups 
(p=0.68), although the event rates were low (1% in the rhythm-control group and 2% 
in the rate control group). 
 
Several other trials did not find any significant benefit of rhythm control vs. rate 
control strategy for stroke prevention in AF. Although these studies were not 
specifically designed for patients with HF, such subjects represented a substantial 
fraction of their participants. The How to Treat Chronic Atrial Fibrillation (HOT 
CAFE) study 
42
 involved patients with mild-moderate HF, but about half of the 
participants had mild HF with  New York Heart Classification (NYHA) class I. In the 
Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study, 
only 26% of participants had impaired LVEF and 23% of subjects had history of 
congestive HF (only 9% of all patients had NYHA functional class ≥II, average 
LVEF was 55%).
43
 In the Rate Control versus Electrical Cardioversion for Persistent 
Atrial Fibrillation RACE 
44
 trial with about a half of the 512 participants having a 
history of symptomatic HF, there was no evidence of superiority of any of the two 
approaches and adequate rate control may be appropriate for patients with HF. 
 
 
Thrombosis prevention in heart failure without atrial fibrillation 
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The pattern of thrombotic complications in HF differs substantially between subjects 
with and without AF. Whilst cardiogenic stroke and systemic thromboembolism is the 
major risk in patients with AF, in those without AF risks related to coronary 
thrombosis dominate. In HF subjects without any history of AF who had NYHA class 
II-III symptoms, the annual rate of systemic VTE was about 1%, which would 
correspond to low risk in patients with AF.
45
 However the risks may be much higher 
in selected HF groups, such as those with advanced congested HF with poor 
mobility.
7, 8
 In subanalysis of the Survival and Ventricular Enlargement (SAVE) trial, 
risk of ischaemic strokes increased by 18% for every 5% reduction in LVEF.
46
 In fact, 
impact of deterioration of left ventricular contractility on VTE risk may be more 
prominent in HF in NSR than in those with AF; and in the Sudden Cardiac Death-HF 
(SCD-Heft) study, this association was noted in subjects in NSR only.
47
 Patients with 
severe HF could be more prone to eventually develop AF, which might not be timely 
reported to clinicians. 
 
Several trials have aimed to establish utility of oral anticoagulants in HF with NSR.
15-
17
 In the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) 
study, patients with impaired left ventricular systolic function (i.e., left ventricular 
ejection fraction <30%) were randomised for warfarin or antiplatelet therapy.
16
 The 
trial showed a trend towards lower annual rates of non-fatal stroke in the warfarin 
group (0.7%) compared to aspirin (2.1%) group and lower and similar trend for 
hospital admission (16.1% in the warfarin group vs. 22.2 % in aspirin group and 
18.3% in clopidogrel group). The positive trend was offset by a significant increase in 
bleeding complications (5.5 % with warfarin vs. 3.6% with aspirin and 2.5% with 
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clopidogrel).
 
Unfortunately, the study lacked statistical power needed to make 
unambiguous conclusions. 
 
The Warfarin Aspirin Reduced Cardiac Ejection Fraction (WARCEF) study was the 
largest trial of oral anticoagulation in HF with NSR. It recruited 2305 patients with 
HFrEF. During mean follow up of 3.5 years, treatment with warfarin as compared to 
325 mg daily dose of aspirin had no impact on the primary outcome of ischemic 
stroke, intracerebral haemorrhage, or any-cause death.
48
 In accordance with the 
WATCH trial, treatment with warfarin in the WARCEF study was associated with 
reduction in ischemic strokes (hazard ratio 0.52; 95% confidence interval 0.33-0.82; 
p=0.005) by the price of almost doubled rate of major bleedings (no difference in 
intracranial or intracerebral was noted). In view of lack of any convincing overall 
benefit of warfarin in patients in NSR, current consensus does not recommend oral 
anticoagulant therapy with vitamin K antagonists in AF-free HF.
1
  
 
As mentioned above, patients with HF in NSR often have background CAD and are at 
high risk of coronary atherothrombotic events. They should receive appropriate 
antiplatelet therapy (typically aspirin with addition of an ADP-inhibitor after 
percutaneous coronary interventions and/or acute coronary syndrome).  Of note, about 
half of cases of SCD in HF are related to coronary atherothrombosis, and over a 
quarter of admissions with acute HF have features of coronary thrombosis, thus 
mandating strict compliance with the recommended antiplatelet regimens.
10 
Favourable safety and efficacy profile of non-vitamin K oral anticoagulants may 
overcome limitations of warfarin in AF-free HF, but this needs to be assessed in 
appropriately designed clinical trial(s). 
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Non-vitamin K oral anticoagulants for use in atrial fibrillation with heart failure 
 
Non-vitamin K oral anticoagulants (NOACs, previously referred to as new or novel 
oral anticoagulants
49
) directed to block activity of specific coagulation factors 
responsible for activation of both intrinsic and extrinsic coagulation pathways have 
been recently approved for stroke prevention in NVAF (Table 1).   
 
Whilst showing efficacy, safety and relative convenience compared to warfarin, the 
NOACs have their own challenges, especially in translating the impressive clinical 
data to everyday clinical practice
50-52
.  
 
Apixaban 
Apixaban is a selective reversible inhibitor of factor Xa. Its effectiveness and safety in 
AF was established in a large Apixaban for the Prevention of Stroke in Subjects With 
Atrial Fibrillation (ARISTOTLE) double-blind noninferiority randomised study 
comparing apixaban (5 mg twice-daily standard dose) with warfarin adjusted to 
maintain INR 2.0-3.0.
53
 (Table 2) All trial patients had at least one additional risk 
factor for stroke. Among 18,201 study participants 35% had HF defined as 
symptomatic HF or LVEF <40%. This study showed that the risk of stroke and 
systemic VTE was equal in the two treatment arms, irrespectively of presence of HF 
(Table 3). The presence of HF also did not affect risk of major bleeding, which was 
similar with both treatments. Bleeding complications annually occurred in 2.2% of 
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HF-free patients receiving apixaban, 1.9% of subjects with HF treated with apixaban 
and 3.1% of patients treated with warfarin (with or without HF).  
 
The ARISTOTLE trial has demonstrated increased risk of the combined end point of 
stroke, systemic VTE or death in patients with HF who have LVEF < 40% (8.1 per 
100 patient-years) compared to 5.32 per 100 patient-years in symptomatic HF with 
LVEF > 40%, and 1.54 per 100 patient-years in participants with no HF and normal 
LVEF(p<0.0001 for all comparisons). Despite this apixaban effectiveness was 
consistent among the three groups.
54
 
 
Rivaroxaban 
Rivaroxaban is a factor Xa inhibitor with concentration-dependent anticoagulation 
effect on oral intake.
55, 56
 The Rivaroxaban Once Daily Oral Direct Factor Xa 
Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and 
Embolism Trial in Atrial Fibrillation (ROCKET AF) trial provided double-blinded 
randomised comparison of rivaroxaban 20 mg once daily (15 mg daily creatinine 
clearance was 30-49 ml/min) or warfarin adjusted to maintain INR 2.0-3.0 in 14264 
patients with AF.
55
; the study included 62.5% of patients with HF. Subjects with HF, 
as compared to those without HF, more frequently had persistent AF (83% and 78%, 
respectively) and had higher average CHADS
2
 score (3.7 and 3.1, respectively). 
Rivaroxaban showed similar effectiveness in people with LVEF <  40% and in those 
with higher LVEF. The agent maintained equal efficacy and safety profiles among 
patients with NYHA class III-IV symptoms as in those with more mild HF symptoms. 
Of importance, the favourable properties of rivaroxaban were consistent in HF 
patients with different risk of stroke or systemic VTE.
57
 Moreover, when intention to 
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treat analysis was applied to patients with HF, rivaroxaban was not associated with 
any increase in major or non-major clinically relevant bleeding. On the other hand, 
treatment with rivaroxaban resulted in lower rates of haemorrhagic stroke in HF 
patients (adjusted hazard ratio 0.38, 95% confidence interval 0.19-0.76). 
 
These findings have been complemented by a study designed to establish 
pharmacokinetic and pharmacodynamic properties of rivaroxaban in patients admitted 
with acute decompensated HF, which  demonstrated that pharmacological 
characteristics of the agent in acute HF were not significantly affected by additional 
thromboprophylaxis with enoxaparin 40 mg daily, which is frequently the current 
routine practice.
58
 
 
Dabigatran etexilate 
Dabigatran is the only oral direct thrombin inhibitor currently used for stroke 
prevention in AF. The Randomized Evaluation of Long-term anticoagulant therapy 
(RE-LY) study randomised 18,113 patients with AF, including 4904 patients with 
symptomatic HF to 110 mg or 150 mg twice daily or open label warfarin (target INR 
2.0-3.0).
55
. Patients with HF were younger than HF- free subjects (68±10 vs. 73±8 
years, respectively) and included a higher proportion of male participants (66.9% vs. 
62.3%).
59
 Patients with LVEF ≤40% represented 43.5% of the study cohort and were 
on average 5 years younger than participants with better LV contractility. There was 
no significant difference in the rate of stroke of systemic VTE among patients with 
HF assigned for different treatment regimens (1.90% with 110 mg dabigatran, 1.44 
with 150mg dabigatran, and 1.85% with warfarin). The annual rates of major 
bleedings in patients with HF were 3.26% with 110 mg dabigatran, 3.10% with 150 
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mg dabigatran and 3.90% with warfarin, confirming a favourable safety profile of 
dabigatran in HF. However, it was noted that patients with HF tended to have lower 
median TTR than subjects without HF. The rates of the most feared complication of 
oral anticoagulation, intracranial bleeding, were lower with the two dabigatran doses 
(hazard ratio 0.39, 95% confidence interval 0.17-0.89 for dabigatran 150 mg vs. 
warfarin; hazard ratio 0.34, 95% confidence interval 0.14-0.80 for dabigatran 110 mg 
vs. warfarin).
59
 
 
 
Conclusions 
 
Oral anticoagulation is essential in the vast majority of HF patients with AF with non-
vitamin K based anticoagulants being suitable alternative to warfarin. In contrast, 
aspirin alone does not provide adequate stroke prevention in such patients. In HF 
without AF, oral anticoagulation should not be routinely used, and antiplatelet agents 
should be prescribed in patients with background CAD. More data on utility of 
NOACs in HF are awaited with interest. 
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Table 1. Pharmacological characteristics of non-vitamin K oral anticoagulants 
 Apixaban Rivaroxaban Dabigatran 
Mode of action Factor Xa inhibitor Factor Xa inhibitor Factor II (thrombin) 
inhibitor 
Dosing Twice daily Once daily Twice daily 
Prodrug No No Yes 
Bioavailability 60% More 60-80% 6% 
Time to peak level, 
hours 
3 3 2 
Half-life, hours 9-14 4-9 (12 in elderly) 14-17 
Renal excretion 20-30% (75% faecal) 35% (35% by liver) 80% 
Interactions Potent 
inhibitors/inducers of 
CYP3A4 and P-gp 
Potent 
inhibitors/inducers of 
CYP3A4 and P-gp 
Potent 
inhibitors/inducers of 
P-gp 
 
 
Table 2. Characteristics of major trials on non-vitamin K oral anticoagulants in atrial 
fibrillation  
 
Trial ARISTOTLE
55
 ROCKET-AF
60
 RE-LY
53
 
Active medication Apixaban Rivaroxaban Dabigatran 
Participant number 18201 14264 18113 
Patients with heart 
failure (% of total) 
2736 (19%) 9033 (64%) 4904 (27%) 
Follow-up duration, 2.1 3.5 2.1 
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years 
Males 2153 (79%)* 5500 (61%)* 3282 (67%)* 
Age, years 68 (60-74) 72 (65-78) 68±3 
CHADS2 score 2.7±1.1 3.7±0.9 2.6±1.1 
Definition of heart 
failure 
Ejection fraction 
<40% or moderate-
severe left 
ventricular 
dysfunction 
History of heart 
failure or ejection 
fraction <40% 
NYHA class ≥ II 
symptoms 6 months 
prior to screening 
and previous HF 
admission 
Ischemic etiology of 
heart failure  
763 (28%)* 2685 (30%)* 1559 (32%)* 
History of diabetes 736 (27%)* 3828 (42%)* 1298 (27%)* 
History of 
hypertension 
2059 (75%)* 8402 (93%)* 3686 (75%)* 
Ejection fraction ≤ 
40% 
Not provided, but 
55% had moderate 
systolic dysfunction; 
31% severe systolic 
dysfunction 
2145 (34%)* 44%* 
Interraction with HF No (p=0.50) No No (p=0.42/p=0.33 
with the 2 doses) 
*Per cent of patients with heart failure 
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Table 3. Outcomes of major trials on non-vitamin K oral anticoagulants in atrial 
fibrillation  
Outcome events, 
per year 
ARISTOTLE 
 
ROCKET-AF 
 
RE-LY 
 
Agent Apixab
an 
Warfari
n 
Rivaroxaba
n 
Warfarin Dabigatran Warfarin 
Stroke or 
systemic 
thromboembolis
m 
 0.99% 1.8% 1.9% 2.1% 1.4% 
 
1.9% 
Death 7.0% 7.2% 5.1% 5.5% Not 
provided 
Not 
provided 
Major bleeding 2.8% 3.4% Not 
provided 
Not 
provided 
3.1% 3.4% 
Intracranial 
bleeding 
0.18% 0.73% 0.4% 0.7% 0.26% 0.65% 
 
 
